To The Moon

Full story: https://grafa.com/en/news/australia/xero-lifts-full-year-revenue-to-1-7b Key points Xero reported $1.7 billion in first-half revenue alongside an upgraded full-year outlook and a new share buy-back program. The board approved an on-market share buy-back program of up to $1 billion over the next 12 months. Growth was driven by customer additions, higher average revenue per user, and expanding multi-product adoption across core global markets. Xero (ASX:XRO) grew first-half fiscal 2027 revenue by 46% to $1.7 billion and announced a share buyback. Adjusted earnings before interest, taxes, depreciation, and amortisation rose 3% to $362 million compared to the previous period. “Our H1 FY27 results show we’re continuing to do what we said we’d do, delivering strong macro-resilient gr

Full story: https://grafa.com/en/news/united-states/airo-group-q3-2026-revenue-jumps-179-percent AIRO Group Holdings (NASDAQ:AIRO) reported third-quarter 2026 revenue of $17.5 million, up 179% from $6.3 million a year earlier, while its net loss widened to $12.0 million from $8 million. Gross profit increased 255% to $9.9 million, lifting gross margin to 57% from 44%, helped by higher-volume drone sales and improved manufacturing efficiency. Operating loss widened to $13.1 million from $12 million, while the adjusted EBITDA loss narrowed to $7.5 million from $8 million as higher operating expenses offset part of the revenue growth. Following the announcement, AIRO shares traded at approximately $5.50, down 1.79% on November 12, 2026. AIRO held $37.8 million in cash and $1.2 million in debt

Full story: https://grafa.com/en/news/united-states/belite-bio-q3-2026-net-loss-30-3-million Key points Belite Bio (NASDAQ:BLTE) reported a third-quarter 2026 net loss of $30.3 million, compared with $21.7 million a year earlier, as research and administrative expenses increased. The company held $271.3 million in cash and cash equivalents and $502.7 million in U.S. Treasury investments at September 30. Its tinlarebant application for Stargardt disease has received FDA priority review, with a February 12, 2027 target decision date, while applications have also been submitted in four other countries. Belite Bio (NASDAQ:BLTE) reported a third-quarter 2026 net loss of $30.3 million, compared with a $21.7 million loss in the same period of 2025. The wider loss followed an increase in research

Full story: https://grafa.com/en/news/united-states/nebius-q3-2026-revenue-jumps-571-percent Key points Nebius Group (NASDAQ:NBIS) reported third-quarter 2026 revenue of $980.8 million, up 571% year over year, with adjusted EBITDA reaching $465.8 million. The company recorded a GAAP net loss of $37.5 million, narrowing from $119.6 million a year earlier. Nebius raised $5.75 billion in debt financing during the quarter as it continued funding its AI infrastructure expansion. Nebius Group (NASDAQ:NBIS) reported third-quarter 2026 revenue of $980.8 million, up 571% year over year, while its net loss from continuing operations narrowed to $37.5 million. Revenue exceeded the analyst consensus estimate of $907.2 million, while adjusted EBITDA reached $465.8 million compared with a loss of $5.2 m

Full story: https://grafa.com/en/news/united-states/allot-q3-2026-revenue-rises-16-percent Key points Allot (NASDAQ:ALLT) reported third-quarter 2026 net income of $3.4 million, or $0.07 per share. Adjusted earnings reached $0.09 per share, while revenue of $30.6 million exceeded the analyst consensus estimate of $30.2 million. The company's shares have declined approximately 9% since the beginning of 2026 and about 2% over the past 12 months. Allot (NASDAQ:ALLT) reported third-quarter 2026 revenue of $30.6 million, up 16% year over year, while GAAP net income increased to $3.4 million, or $0.07 per diluted share. Revenue exceeded the Zacks analyst consensus estimate of $30.2 million, while net income increased from $2.8 million a year earlier and adjusted earnings reached $0.09 per share,

Full story: https://grafa.com/en/news/united-states/rockwell-medical-q3-2026-sales-rise-20-percent Key points Rockwell Medical (NASDAQ:RMTI) reported third-quarter 2026 net sales of $19.1 million, up 20% from $15.9 million a year earlier. Gross profit increased 37% to $3.1 million, while gross margin improved to 16% from 14%; quarterly net loss widened to $2.3 million. The proposed combination with Vantive's hemodialysis business is projected by the company to generate annual revenue of $400 million–$450 million. Rockwell Medical (NASDAQ:RMTI) reported third-quarter 2026 net sales of $19.1 million, up 20% year over year, while its net loss widened to $2.3 million, or $0.59 per share. Revenue increased from $15.9 million a year earlier, while gross profit rose 37% to $3.1 million and gross

Full story: https://grafa.com/en/news/united-states/yeti-q3-2026-results-lowers-full-year-outlook Key points YETI Holdings (NYSE:YETI) reported third-quarter 2026 net sales of $509.4 million, up 4%, while adjusted sales increased 6% to $517.9 million. Adjusted diluted earnings per share rose 49% to $0.91, while gross margin expanded 180 basis points to 57.7%. YETI lowered its full-year adjusted sales growth forecast to approximately 6% and reduced adjusted EPS guidance to $2.90–$2.95, citing cautious consumer spending. YETI Holdings (NYSE:YETI) reported third-quarter 2026 net sales of $509.4 million, up 4%, while lowering its full-year adjusted sales and earnings outlook. Reported sales missed analysts' approximately $523 million estimate, while adjusted sales rose 6% to $517.9 million and

Full story: https://grafa.com/en/news/united-states/prudential-advisory-sales-record-1-4-billion-q3-2026 Key points Prudential Financial (NYSE:PRU) reported record third-quarter 2026 sales of approximately $1.4 billion at its U.S. advisory business. Client assets reached approximately $80 billion, up from nearly $50 billion four years ago. The business added more than 450 experienced financial advisors over 18 months and continues expanding its wealth management capabilities through its LPL Financial relationship. Prudential Financial (NYSE:PRU) reported approximately $1.4 billion in record third-quarter 2026 sales at its U.S. advisory business, Prudential Wealth Advisors. The business also recorded its highest monthly sales in September, while total revenue increased 20% over two years. C

Full story: https://grafa.com/en/news/united-states/dingdong-q3-2026-revenue-rises-10-8-percent Key points Dingdong (NYSE:DDL) reported third-quarter 2026 revenue of RMB7,380.4 million, up 10.8% year over year, while net income increased 259.6% to RMB298.1 million. Gross margin improved to 29.7% from 28.9%, while gross merchandise value rose 14.3% to RMB8,311.1 million. The pending sale of its China business to Meituan remains subject to regulatory approval, including clearance from China's SAMR. Dingdong (NYSE:DDL) reported third-quarter 2026 revenue of RMB7,380.4 million, up 10.8%, while net income rose 259.6% to RMB298.1 million. Revenue compared with RMB6,662.4 million a year earlier, while gross merchandise value rose 14.3% to RMB8,311.1 million from RMB7,273.2 million. Gross margin r

Full story: https://grafa.com/en/news/united-states/standard-nuclear-q3-2026-backlog-doubles-577-million Key points Standard Nuclear (NYSE:STDN) reported third-quarter 2026 revenue of $6.0 million, compared with $0.9 million a year earlier, and completed its first commercial reactor core fuel delivery. Total contract backlog more than doubled to $577.2 million, while funded backlog nearly doubled to $119.6 million at September 30, 2026. The company is preparing to expand production at its Tennessee and Idaho facilities, targeting Department of Energy operating authorization in February 2027. Standard Nuclear (NYSE:STDN) reported third-quarter 2026 revenue of $6 million, up from $0.9 million a year earlier, as total contract backlog more than doubled to $577.2 million at September 30. The c